Luke Evnin

Prior to co-founding MPM in 1997, Luke Evnin was employed by the venture capital firm Accel Partners. He received his PhD in Biochemistry from the University of California – San Francisco. He has devoted significant efforts since 2000 to working with the Scleroderma Research Foundation, serving as Chairman since 2002. Dr. Evnin also devotes energy to the External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics at Princeton, the External Advisory Boards for QB3, the Mission Bay Capital Fund at UCSF, and the Boston University Scleroderma CORT.